Literature DB >> 3881558

Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal.

B J Rounsaville, T Kosten, H Kleber.   

Abstract

Two controlled trials have suggested that clonidine can be used on an outpatient basis to assist in opioid withdrawal, but that rates of successful detoxification do not exceed those obtained with gradual methadone reduction. This study examines the process of clonidine-and methadone-assisted detoxification to provide information about the timing and severity of withdrawal symptoms and side effects associated with each of the two methods. Derived from a double-blind clinical trial with randomized treatment assignment, data are presented which might guide the clinician in the choice of detoxification methods. In this study, subjects in either treatment condition had a success rate of approximately 40% and most subjects experienced at least moderate withdrawal discomfort in the areas of difficulty sleeping, feeling "blah," and craving. In both treatment groups the best predictor of detoxification failure was a high level of psychological symptoms at the onset of the study. Compared with gradual methadone reduction, clonidine treatment resulted in higher levels of withdrawal symptoms and side effects, earlier onset of withdrawal discomfort, earlier attrition, earlier termination of withdrawal discomfort, and a posttreatment course of drug use that was more consistent with success status during the study treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881558     DOI: 10.1097/00005053-198502000-00007

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  18 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

3.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

4.  [The drug addict in prison: Medical response and its limitations].

Authors:  R Jeanmonod; T Harding
Journal:  Soz Praventivmed       Date:  1988

5.  Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration.

Authors:  Kathryn L Hamilton; Andrew C Harris; Jonathan C Gewirtz
Journal:  Brain Res       Date:  2013-09-26       Impact factor: 3.252

6.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

Review 7.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

9.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Authors:  Leslie Amass; Walter Ling; Thomas E Freese; Chris Reiber; Jeffrey J Annon; Allan J Cohen; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Cynthia Clark; Douglas M Ziedonis; Jonathan Krejci; Susan Stine; Theresa Winhusen; Greg Brigham; Dean Babcock; Joan A Muir; Betty J Buchan; Terry Horton
Journal:  Am J Addict       Date:  2004

Review 10.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.